The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

For people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting ...

In patients with T2D, GLP-1s don’t increase the risk for acute pancreatitis, mitigate the risk for complications in those who ...

After questions and criticism online, Janelle Rohner says she should have disclosed her decision to take a GLP-1.

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

Glucagon-like peptide 1 receptor agonist treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms.

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...

If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...